Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer - Cnam - Conservatoire national des arts et métiers Accéder directement au contenu
Article Dans Une Revue Clinical Cancer Research Année : 2021

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

Emmanuelle Jeannot
Guillaume Bataillon
Célia Dupain
Marina Popovic
  • Fonction : Auteur
Ekaterina S Jordanova
Diana Bello Roufai

Résumé

Purpose: Almost all cervical cancers are caused by human papillomavirus (HPV) and patients with advanced stage are at high risk for relapse. Circulating HPV DNA (HPV ctDNA) may serve as a residual tumor marker at the end of chemoradiation or to predict relapse during the follow-up period. Experimental Design: We analyzed serum samples from 94 HPV16-or HPV18-related CCs from the BioRAIDs prospective cohort. Samples were collected before and after treatment and during an 18-month follow-up period. Using digital droplet PCR (ddPCR), we assessed the relevance of circulating HPV E7 gene as a marker for residual disease compared to HPV integration site and PIK3CA mutations. Finally, the prognostic impact of circulating HPV E7 gene was assessed with its prediction value of relapse. Results: HPV E7 gene was the most sensitive tumor marker, superior to both HPV integration sites and PIK3CA mutations in serum. Circulating HPV DNA (HPV ctDNA) was detected in 63% (59/94) of patients, before treatment. HPV ctDNA detection in serum sample was associated with high FIGO stage (P ¼ 0.02) and para-aortic lymph node involvement (P ¼ 0.01). The level of HPV ctDNA was positively correlated with HPV copy number in the tumor (R ¼ 0.39, P < 0.001). Complete clearance of HPV ctDNA by the end of treatment was significantly associated with a longer PFS (P < 0.0001). Patients with persistent HPV ctDNA in serum relapsed with a median time of 10 months (range, 2-15) from HPV ctDNA detection. Conclusions: HPV ctDNA detection is a useful marker to predict relapse in cervical cancer. See related commentary by Wentzensen and Clarke, p. 5733
Fichier principal
Vignette du fichier
Circulating_HPV_DNA_as_a_Marker_for_Early_Detection_of_Relapse_in_Patients_with_Cervical_Cancer.pdf (1.08 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03733979 , version 1 (21-07-2022)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Emmanuelle Jeannot, Aurélien Latouche, Claire Bonneau, Marie-Ange Calméjane, Corine Beaufort, et al.. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer. Clinical Cancer Research, 2021, 27 (21), pp.5869 - 5877. ⟨10.1158/1078-0432.ccr-21-0625⟩. ⟨hal-03733979⟩
78 Consultations
96 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More